Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants.

Chen, H; Chen, J; Zhang, F; Li, Y; Wang, R; Zheng, Q; Zhang, X; Zeng, J; Xu, F; Lin, Y

Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants.

Chen, H Chen, J Zhang, F Li, Y Wang, R Zheng, Q Zhang, X Zeng, J Xu, F Lin, Y

Permalink

Publisher:: Frontiers
Publication Type:: Journal Article
Citation:: Front Cardiovasc Med, 2022, 9, pp. 964977
Issue Date:: 2022

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (357.57 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Chen, H
dc.contributor.author	Chen, J
dc.contributor.author	Zhang, F
dc.contributor.author	Li, Y
dc.contributor.author	Wang, R
dc.contributor.author	Zheng, Q
dc.contributor.author	Zhang, X
dc.contributor.author	Zeng, J
dc.contributor.author	Xu, F
dc.contributor.author	Lin, Y https://orcid.org/0000-0002-4637-9701
dc.date.accessioned	2023-06-30T21:23:22Z
dc.date.available	2022-07-21
dc.date.available	2023-06-30T21:23:22Z
dc.date.issued	2022
dc.identifier.citation	Front Cardiovasc Med, 2022, 9, pp. 964977
dc.identifier.issn	2297-055X
dc.identifier.issn	2297-055X
dc.identifier.uri	http://hdl.handle.net/10453/171054
dc.description.abstract	Nattokinase (NK), known as a potent fibrinolytic and antithrombotic agent, has been shown to have antiatherosclerotic and lipid-lowering effects. However, data on human clinical studies are limited. In this clinical study involving 1,062 participants, our objective was to examine the efficacy of NK in atherosclerosis and hyperlipidemia and safety at the dose of 10,800 FU/day after 12 months of oral administration. Various factors, including lower doses that influence NK pharmacological actions, were also investigated. We found that NK at a dose of 10,800 FU/day effectively managed the progression of atherosclerosis and hyperlipidemia with a significant improvement in the lipid profile. A significant reduction in the thickness of the carotid artery intima-media and the size of the carotid plaque was observed. The improvement rates ranged from 66.5 to 95.4%. NK was found to be ineffective in lowering lipids and suppressing atherosclerosis progression at a dose of 3,600 FU/day. The lipid-lowering effect of NK was more prominent in subjects who smoked, drank alcohol, and subjects with higher BMI. Regular exercise further improved the effects of NK. Co-administration of vitamin K2 and aspirin with NK produced a synergetic effect. No noticeable adverse effects associated with the use of NK were recorded. In conclusion, our data demonstrate that atherosclerosis progression and hyperlipidemia can be effectively managed with NK at a dose of 10,800 FU/day. The lower dose of 3,600 FU per day is ineffective. The dose of 10,800 FU/day is safe and well tolerated. Some lifestyle factors and the coadministration of vitamin K2 and aspirin lead to improved outcomes in the use of NK. Our findings provide clinical evidence on the effective dose of NK in the management of cardiovascular disease and challenge the recommended dose of 2,000 FU per day.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	Frontiers
dc.relation.ispartof	Front Cardiovasc Med
dc.relation.isbasedon	10.3389/fcvm.2022.964977
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants.
dc.type	Journal Article
utslib.citation.volume	9
utslib.location.activity	Switzerland
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access	*
dc.date.updated	2023-06-30T21:23:19Z
pubs.publication-status	Published online
pubs.volume	9

Abstract:

Nattokinase (NK), known as a potent fibrinolytic and antithrombotic agent, has been shown to have antiatherosclerotic and lipid-lowering effects. However, data on human clinical studies are limited. In this clinical study involving 1,062 participants, our objective was to examine the efficacy of NK in atherosclerosis and hyperlipidemia and safety at the dose of 10,800 FU/day after 12 months of oral administration. Various factors, including lower doses that influence NK pharmacological actions, were also investigated. We found that NK at a dose of 10,800 FU/day effectively managed the progression of atherosclerosis and hyperlipidemia with a significant improvement in the lipid profile. A significant reduction in the thickness of the carotid artery intima-media and the size of the carotid plaque was observed. The improvement rates ranged from 66.5 to 95.4%. NK was found to be ineffective in lowering lipids and suppressing atherosclerosis progression at a dose of 3,600 FU/day. The lipid-lowering effect of NK was more prominent in subjects who smoked, drank alcohol, and subjects with higher BMI. Regular exercise further improved the effects of NK. Co-administration of vitamin K2 and aspirin with NK produced a synergetic effect. No noticeable adverse effects associated with the use of NK were recorded. In conclusion, our data demonstrate that atherosclerosis progression and hyperlipidemia can be effectively managed with NK at a dose of 10,800 FU/day. The lower dose of 3,600 FU per day is ineffective. The dose of 10,800 FU/day is safe and well tolerated. Some lifestyle factors and the coadministration of vitamin K2 and aspirin lead to improved outcomes in the use of NK. Our findings provide clinical evidence on the effective dose of NK in the management of cardiovascular disease and challenge the recommended dose of 2,000 FU per day.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/171054